المؤلفون: von Arx C; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. Electronic address: claudia.vonarx@istitutotumori.na.it., De Placido P; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Caltavituro A; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Di Rienzo R; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Buonaiuto R; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., De Laurentiis M; Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Arpino G; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Puglisi F; Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy; Department of Medicine (DAME), University of Udine, Udine, Italy., Giuliano M; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Del Mastro L; Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy.

المصدر: Cancer treatment reviews [Cancer Treat Rev] 2023 Feb; Vol. 113, pp. 102500. Date of Electronic Publication: 2022 Dec 24.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use , Immunoconjugates*/pharmacology , Immunoconjugates*/therapeutic use, Humans ; Female ; Antibodies, Monoclonal, Humanized/therapeutic use ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; Ado-Trastuzumab Emtansine/therapeutic use ; Ado-Trastuzumab Emtansine/pharmacology ; Receptor, ErbB-2/metabolism ; Antibodies, Monoclonal/therapeutic use

المؤلفون: Cocco S; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Leone A; Experimental Pharmacology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Piezzo M; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Caputo R; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Di Lauro V; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Di Rella F; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Fusco G; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Capozzi M; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Gioia GD; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., Budillon A; Experimental Pharmacology Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy., De Laurentiis M; Breast Unit, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Via Mariano Semmola 53, 80131 Napoli, Italy.

المصدر: International journal of molecular sciences [Int J Mol Sci] 2020 Oct 22; Vol. 21 (21). Date of Electronic Publication: 2020 Oct 22.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Autophagy/*drug effects , Breast Neoplasms/*drug therapy , Breast Neoplasms/*pathology, Antineoplastic Agents/therapeutic use ; Autophagy/physiology ; Breast Neoplasms/metabolism ; Clinical Trials as Topic ; Female ; Humans ; Molecular Targeted Therapy/methods ; Phosphatidylinositol 3-Kinases/metabolism ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; TOR Serine-Threonine Kinases/metabolism ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/metabolism ; Triple Negative Breast Neoplasms/pathology ; Tumor Microenvironment

المؤلفون: Gligorov J; APHP-Tenon, IUC-UPMC, Sorbonne University, Paris, France. Electronic address: joseph.gligorov@aphp.fr., Ataseven B; Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany., Verrill M; Northern Centre for Cancer Care, Medical Oncology Department, Newcastle, UK., De Laurentiis M; Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Division of Breast Oncology, Naples, Italy., Jung KH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Azim HA; Cairo University, Clinical Oncology Department, Cairo, Egypt., Al-Sakaff N; F. Hoffmann-La Roche Ltd, Global Pharma Development, Basel, Switzerland., Lauer S; F. Hoffmann-La Roche Ltd, Biostatistics, Basel, Switzerland., Shing M; Genentech, Inc., Global Pharma Development, South San Francisco, CA, USA., Pivot X; University Hospital Jean Minjoz, INSERM 1098, Besançon, France.

مؤلفون مشاركون: SafeHer Study Group

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 Sep; Vol. 82, pp. 237-246. Date of Electronic Publication: 2017 Jun 16.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Breast Neoplasms/*drug therapy , Trastuzumab/*administration & dosage, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Breast Neoplasms/metabolism ; Chemotherapy, Adjuvant ; Female ; Humans ; Injections, Subcutaneous/adverse effects ; Middle Aged ; Receptor, ErbB-2/metabolism ; Survival Analysis ; Trastuzumab/adverse effects ; Young Adult

المؤلفون: Caputo R; S.C. Oncologia Medica Senologica, Istituto Nazionale Tumori Napoli, Naples, Italy., Cianniello D; S.C. Oncologia Medica Senologica, Istituto Nazionale Tumori Napoli, Naples, Italy., De Laurentiis M; S.C. Oncologia Medica Senologica, Istituto Nazionale Tumori Napoli, Naples, Italy.

المصدر: Future oncology (London, England) [Future Oncol] 2017 Apr; Vol. 13 (11s), pp. 45-50.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Breast Neoplasms/*drug therapy , Breast Neoplasms/*pathology , Furans/*therapeutic use , Ketones/*therapeutic use, Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Breast Neoplasms/diagnosis ; Combined Modality Therapy ; Comorbidity ; Female ; Furans/administration & dosage ; Furans/adverse effects ; Humans ; Ketones/administration & dosage ; Ketones/adverse effects ; Middle Aged ; Neoplasm Metastasis ; Positron Emission Tomography Computed Tomography ; Retreatment ; Treatment Outcome

المؤلفون: Sini V;  Oncology Unit, Sant'Andrea Hospital, Sapienza University of Rome, and Oncology Unit ASL Roma 1 Santo Spirito Hospital, Rome - Italy., Cassano A;  Division of Medical Oncology, Catholic University of Sacred Heart, Rome - Italy., Corsi D;  Oncology Unit, San Giovanni Calabita Hospital, Rome - Italy., De Laurentiis M;  Department of Breast Oncology, National Cancer Institute 'Fondazione Pascale,' Naples - Italy., Gamucci T;  Medical Oncology Unit ASL Frosinone, Frosinone - Italy., Mauri M;  Oncology Unit, San Giovanni Hospital, Rome - Italy., Naso G;  Oncology B Unit, Sapienza University of Rome, Rome - Italy., Roselli M;  Oncology Unit, Tor Vergata University of Rome, Rome - Italy., Ruggeri EM;  Division of Medical Oncology, Belcolle Hospital, ASL Viterbo, Viterbo - Italy., Tonini G;  Department of Medical Oncology, University Campus Bio-Medico, Rome - Italy., Vici P;  Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome - Italy., Zampa G;  Oncology Unit, Nuovo Regina Margherita Hospital, Rome - Italy., Marchetti P;  Oncology Unit, Sant'Andrea Hospital, Sapienza University of Rome, and Oncology Unit, IDI-IRCCS, Rome - Italy.

المصدر: Tumori [Tumori] 2016 Oct 13; Vol. 102 (5), pp. 472-480. Date of Electronic Publication: 2016 Aug 23.

نوع المنشور: Journal Article; Meta-Analysis; Review

بيانات الدورية: Publisher: Sage Publications Country of Publication: United States NLM ID: 0111356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2038-2529 (Electronic) Linking ISSN: 03008916 NLM ISO Abbreviation: Tumori Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Antineoplastic Agents/*therapeutic use , Bevacizumab/*therapeutic use , Breast Neoplasms/*drug therapy , Breast Neoplasms/*metabolism , Receptor, ErbB-2/*deficiency, Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Breast Neoplasms/pathology ; Clinical Trials as Topic ; Female ; Humans ; Molecular Targeted Therapy ; Neoplasm Staging ; Treatment Outcome

المؤلفون: Maurea N; aDivision of Cardiology, Istituto Nazionale per lo Studio e la Cura dei Tumor 'Fondazione Giovanni Pascale' - IRCCS bCEINGE Biotecnologie Avanzate S.C.A.R.L cDepartment of Breast Surgery and Cancer Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS dDepartment of Molecular Medicine and Medical Biotechnology, University 'Federico II' eDepartment of Senology, Division of Breast Oncology Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione Giovanni Pascale' - IRCCS, Naples fClinic of Cardiovascular Diseases, IRCCS San Martino IST, Genoa gDepartment of Medical Sciences 'Mario Aresu', University of Cagliari, Cagliari, Italy., Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G

المصدر: Journal of cardiovascular medicine (Hagerstown, Md.) [J Cardiovasc Med (Hagerstown)] 2016 May; Vol. 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection, pp. e19-e26.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101259752 Publication Model: Print Cited Medium: Internet ISSN: 1558-2035 (Electronic) Linking ISSN: 15582027 NLM ISO Abbreviation: J Cardiovasc Med (Hagerstown) Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*adverse effects , Antineoplastic Agents/*adverse effects , Breast Neoplasms/*drug therapy , Cardiotoxicity/*physiopathology , Trastuzumab/*adverse effects, Animals ; Cardiotoxicity/etiology ; Female ; Heart/physiopathology ; Heart Failure/chemically induced ; Humans ; Mice ; Receptor, ErbB-2/antagonists & inhibitors ; Signal Transduction/drug effects ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Ventricular Dysfunction, Left/chemically induced

المؤلفون: Criscitiello C; Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy. Electronic address: carmen.criscitiello@ieo.it., Viale G; Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy., Gelao L; Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy., Esposito A; Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy., De Laurentiis M; Department of Breast Oncology, National Cancer Institute 'Fondazione Pascale', Naples, Italy., De Placido S; Department of Endocrinology and Molecular and Clinical Oncology, University of Naples Federico II, Napoli, Italy., Santangelo M; Department of Advanced Medical Sciences, Operative Unit of General Surgery and Transplants, University of Naples Federico II, Napoli, Italy., Goldhirsch A; Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy., Curigliano G; Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy.

المصدر: Cancer treatment reviews [Cancer Treat Rev] 2015 Feb; Vol. 41 (2), pp. 61-8. Date of Electronic Publication: 2014 Dec 08.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Bone Density Conservation Agents/*pharmacology , Bone Neoplasms/*immunology , Bone Remodeling/*immunology , Bone Resorption/*immunology , Bone and Bones/*metabolism , Diphosphonates/*pharmacology , Osteoclasts/*drug effects , RANK Ligand/*metabolism, Animals ; Antibodies, Monoclonal, Humanized/pharmacology ; Antineoplastic Agents/therapeutic use ; Bone Diseases/immunology ; Bone Neoplasms/drug therapy ; Bone Neoplasms/secondary ; Bone and Bones/immunology ; Clodronic Acid/pharmacology ; Denosumab ; Diphosphonates/therapeutic use ; Humans ; Ibandronic Acid ; Imidazoles/pharmacology ; Immune System ; Osteoclasts/immunology ; Osteoprotegerin/drug effects ; Osteoprotegerin/metabolism ; Pamidronate ; RANK Ligand/antagonists & inhibitors ; Receptor Activator of Nuclear Factor-kappa B/drug effects ; Receptor Activator of Nuclear Factor-kappa B/metabolism ; Signal Transduction/drug effects ; Treatment Outcome ; Zoledronic Acid

المؤلفون: De Tursi M, Carella C, Tomao S, Cinieri S, Lorusso V, Marchetti P, Vecchio S, Sansoni E, Contu A, Adamo V, Silvestris N, Nuzzo A, Rosti G, Ravaioli A, Danova M, Tonini G, Passalacqua R, Cruciani G, Faedi M, Spada M, De Laurentiis M, Amoroso D, Tomao F, Sperduti I, Grassadonia A, Tinari N, Natoli C, Iacobelli S

مؤلفون مشاركون: Consorzio Interuniversitario Nazionale per la Bio-Oncologia

المصدر: Tumori [Tumori] 2014 Nov-Dec; Vol. 100 (6), pp. e309-13.

نوع المنشور: Journal Article; Multicenter Study; Observational Study

بيانات الدورية: Publisher: Sage Publications Country of Publication: United States NLM ID: 0111356 Publication Model: Print Cited Medium: Internet ISSN: 2038-2529 (Electronic) Linking ISSN: 03008916 NLM ISO Abbreviation: Tumori Subsets: MEDLINE

مواضيع طبية MeSH: Antiemetics/*therapeutic use , Antineoplastic Agents/*adverse effects , Nausea/*chemically induced , Nausea/*prevention & control , Serotonin 5-HT3 Receptor Antagonists/*therapeutic use , Vomiting/*chemically induced , Vomiting/*prevention & control, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cancer Care Facilities ; Female ; Humans ; Italy ; Male ; Middle Aged ; Neoplasms/drug therapy ; Neurokinin-1 Receptor Antagonists/therapeutic use ; Practice Guidelines as Topic ; Prospective Studies

المؤلفون: Harbeck N; Departments of Oncology, Breast Center, Department of Obstetrics and Gynecology, University of Cologne, Cologne, Germany. Electronic address: nadia.harbeck@uk-koeln.de., Ewer MS; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, USA., De Laurentiis M; Department of Endocrinology and Molecular and Clinical Oncology, University Federico II, Naples, Italy., Suter TM; Swiss Cardiovascular Center and Cardio-Oncology, Bern University Hospital, Bern, Switzerland., Ewer SM; Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2011 Jun; Vol. 22 (6), pp. 1250-1258. Date of Electronic Publication: 2010 Nov 26.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*adverse effects , Breast Neoplasms/*drug therapy , Cardiovascular Diseases/*complications , Chemotherapy, Adjuvant/*adverse effects, Antineoplastic Agents/therapeutic use ; Biomarkers ; Female ; Heart/drug effects ; Humans

المؤلفون: Gori S; Medical Oncology SM della Misericordia Hospital, Azienda Ospedaliera, Perugia, Italy. stefania.gori@tin.it, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M

مؤلفون مشاركون: AIOM Working Group Interaction with Regional Sections (2007-2009)

المصدر: Tumori [Tumori] 2010 Nov-Dec; Vol. 96 (6), pp. 1010-5.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Sage Publications Country of Publication: United States NLM ID: 0111356 Publication Model: Print Cited Medium: Print ISSN: 0300-8916 (Print) Linking ISSN: 03008916 NLM ISO Abbreviation: Tumori Subsets: MEDLINE

مواضيع طبية MeSH: Drug and Narcotic Control*/legislation & jurisprudence , Drug and Narcotic Control*/statistics & numerical data , Pharmacopoeias as Topic*/standards, Antineoplastic Agents/*supply & distribution , Healthcare Disparities/*statistics & numerical data, Antineoplastic Agents/therapeutic use ; Formularies as Topic ; Health Care Surveys ; Humans ; Italy ; Neoplasms/drug therapy ; Societies, Medical